JAGX Jaguar Health, Inc. stock chart & analysis
Conviction 45HealthcareScan · Tue, Nov 10, 2026Jaguar Health, Inc. (JAGX) closed at $0.4352 (-0.21%) on Nov 10, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 37, RS Rating 1, -99.9% from its 52-week high, -99.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why JAGX moved
From the StockSetups movers recaps that covered JAGX, newest first. A recap states what was known that day.
- After hours+34.5%
The catalyst here is well-documented. According to headlines from Yahoo Finance, TradingView, and AD HOC NEWS (October 3–4, 2026), Jaguar Health declared a special stock dividend tied to a five-for-one conversion of its Series R Preferred shares.
After-Hours Movers Oct 5, 2026: OLOX, JAGX, QTEX → - Premarket+33.7%
Context here is everything. The catalyst for today's bounce is largely technical and mechanical — JAGX is recovering from an extreme two-day collapse.
Premarket Movers Sept 25, 2026: INLF, MGLD, AIFF →
Financials as of Tue, Jun 30, 2026 · quarterly.
JAGX technical analysis
Trend
JAGX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 90.1% below the 50-day ($4.41) and 99.4% below the 200-day ($73.33). ADX(14) at 33 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 37, in the bearish half of its range. MACD crossed above its signal line on the latest session. A bullish MACD divergence is in place. Its RS Rating of 1 puts its weighted 12-month performance ahead of about 1% of the US market.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $1.4M a day on average. ATR(14) is $0.8686, 199.6% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.15) shows distribution.
Key levels
The chart pattern's support is $1.18 and its resistance $24.40. The 52-week range is $0.3600 to $712.80; price is 99.9% below the high and 20.9% above the low. The VWAP anchored at the 52-week high is $12.24, above price.
Performance
JAGX returned -21.9% (1 week), -90.6% (1 month), -95.2% (3 months), -98.9% (6 months), -99.9% (1 year), -99.9% (year to date).
About Jaguar Health, Inc.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Pharmaceutical Preparations · Listed 2015 · 47 employees
Recent news
- Jaguar Health, Inc.: Resale prospectusSEC EDGAR · Mon, Nov 9, 2026
- Jaguar Health, Inc.: Follow-on stock offering (dilution)SEC EDGAR · Mon, Nov 9, 2026
- Jaguar Health, Inc.: 8-K filedSEC EDGAR · Fri, Nov 6, 2026
SEC filings
EDGAR filings in JAGX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.